Treating inflammation with soluble hybrid fcgamma receptors

Abstract

Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides.

What is claimed is: 
     
         1 . A method of reducing IgG-mediated inflammation in a subject, the method comprising:
 administering to the subject with IgG-mediated inflammation a therapeutically effective amount of a soluble polypeptide comprising amino acid residues 43-310 of SEQ ID NO:42, amino acid residues 21-286 of SEQ ID NO:44; or amino acid residues 21-286 of SEQ ID NO:46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG.   
     
     
         2 . The method of  claim 1 , wherein the IgG-mediated inflammation is immune complex-mediated. 
     
     
         3 . A method of treating an IgG-mediated inflammatory disease in a subject, the method comprising: administering to the subject a therapeutically effective amount of a soluble polypeptide comprising amino acid residues 43-310 of SEQ ID NO:42, amino acid residues 21-286 of SEQ ID NO:44, or amino acid residues 21-286 of SEQ ID NO:46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG. 
     
     
         4 . The method of  claim 3 , wherein the IgG-mediated inflammatory disease is selected from the group consisting of rheumatoid arthritis (RA); systemic lupus erythematosus (SLE); idiopathic thrombocytopenia purpura (ITP); Sjogren's syndrome; Guillain-Barre syndrome; and Goodpasture's syndrome. 
     
     
         5 . A method of treating an IgG-mediated inflammatory disease in a subject, the method comprising: administering to the subject a therapeutically effective amount of a composition comprising a soluble polypeptide and a pharmaceutically acceptable carrier, wherein the soluble polypeptide comprises amino acid residues 43-310 of SEQ ID NO:42, amino acid residues 21-286 of SEQ ID NO:44, or amino acid residues 21-286 of SEQ ID NO:46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG. 
     
     
         6 . The method of  claim 5 , wherein the IgG-mediated inflammatory disease is selected from the group consisting of rheumatoid arthritis (RA); systemic lupus erythematosus (SLE); idiopathic thrombocytopenia purpura (ITP); Sjogren's syndrome; Guillain-Barre syndrome; and Goodpasture's syndrome.